The prevalence of nonalcoholic fatty liver disease (NAFLD) in the general population is
estimated at 25%, and there is currently no effective treatment of NAFLD. Although insulin …

With the high prevalence of obesity, diabetes, and other features of the metabolic syndrome
in United States, nonalcoholic fatty liver disease (NAFLD) has inevitably become a very …

The prevalence of nonalcoholic fatty liver disease (NAFLD) worldwide has increased at an
alarming rate, which will likely result in enormous medical and economic burden. NAFLD …

Peroxisome proliferator-activated receptor gamma (PPARγ or PPARG) is a ligand-activated
transcription factor belonging to the nuclear hormone receptor superfamily. It plays a master …

Ligand-activated nuclear receptors, including peroxisome proliferator-activated receptor
alpha (PPARα), pregnane X receptor, and constitutive androstane receptor, were first …

Non-alcoholic fatty liver disease (NAFLD) is a complex disease, affecting not just the liver,
but also all other organs in the body. Despite an increasing amount of people worldwide …

Non-alcoholic fatty liver disease (NAFLD) is a metabolic disorder affecting over one quarter
of the global population. Liver fat accumulation in NAFLD is promoted by increased de novo …

Non-alcoholic fatty liver disease (NAFLD) affects one-third of the population worldwide, of
which a substantial number of patients suffer from non-alcoholic steatohepatitis (NASH) …

Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver
disease in adults and children worldwide. The symptoms of NAFLD range from simple …

Nuclear receptors are transcription factors which sense changing environmental or
hormonal signals and effect transcriptional changes to regulate core life functions including …